Cleantech Transit, Inc. (CLNO)
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
Many combinations of biomass source, process and technology are possible. In general, materials with high moisture content (such as sugar cane) are more suited to biochemical conversion and anaerobic digestion than to other forms of conversion. There are many combination of biomass source; but direct combustion is the most fully developed process.
The main processes for utilizing biomass sources include:
o Direct combustion, usually of solids, in boilers or furnaces
o Gasification via a physical or chemical conversion process to a secondary gaseous fuel, followed by combustion in an engine, boiler or turbine
o Biological conversion, via bacterial anaerobic digestion to methane-rich biogas for use as a gaseous fuel
o Chemical or biochemical conversion to produce methanol, ethanol or other liquid fuels.
For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com
Socket Mobile, Inc. (Nasdaq:SCKT) announced the introduction of a new, low-cost barcode scanner, the Socket Bluetooth� Cordless Hand Scanner� (CHS) Model 7C. The CHS 7C includes many of the performance specifications of other Socket 1D barcode scanners. The entire family of CHS barcode scanners offers users the ability to add rapid and robust barcode scanning to smartphones, tablets, notebooks and desktop computing platforms.
Socket Mobile, Inc. produces mobile computing hardware systems for the business mobility market. It offers a family of mobile handheld computer products, which are designed for the healthcare and hospitality markets, as well as accessory products, such as a back pack to enable direct connections to mobile phone networks using network phone cards and a durable case to provide protection in the event the computer is dropped.
Seven Arts Pictures plc (Nasdaq:SAPX) announced that it has closed an initial funding for two films to be produced by Dark Arts a division of Seven Arts’ affiliate, Esplanade Pictures LLC (”Esplanade”). Esplanade will specialize in producing low-budget genre pictures in Louisiana, building on the strength and resources of its local Seven Arts’ affiliate Seven Arts Pictures Louisiana LLC.
Seven Arts Entertainment Inc. operates as an independent motion picture production and distribution company. It engages in the development, acquisition, financing, production, and licensing of theatrical motion pictures for exhibition in theatrical markets worldwide.
Enzo Biochem, Inc. (ENZ)
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since ENZ was founded in 1976, their strategic focus has been on the development of enabling technologies in the life sciences field.
Enzo Biochem Inc. recently announced that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.
The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.
Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.
Biotechnology has been considered with respect to two characteristics: obtaining the best catalyst and the best environment. The most effective, stable and convenient form for the biocatalyst is a whole organism. In most cases, this could be some type of microbe like bacterium, yeast, or mold. Originally, these microorganisms were extracted from the natural environment, but today, scientists can genetically alter these into superior organisms. This is a practice that is being carried out by most biological-based industries and is direct result of the close cooperation between technologists and geneticists.
For more information about Enzo Biochem Inc. visit its website: http://www.enzo.com
Athersys, Inc. (Nasdaq:ATHX) announced that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will present at the 18th Annual Newsmakers in the Biotech Industry Conference to be held on Friday, October 21, 2011 at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York City.
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases.
No comments:
Post a Comment